Technical Report on Biotechnology Stocks -- Amgen, ZIOPHARM Oncology, Sarepta Therapeutics, CTI BioPharma, and Agenus
NEW YORK, September 28, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Sarepta Therapeutics Inc. (NASDAQ: SRPT), CTI BioPharma Corporation (NYSE: CTIC), and Agenus Inc. (NASDAQ: AGEN). Free research report on Amgen can be accessed at https://www.erionline.net/AMGN.pdf On Friday, September 25, 2015, the NASDAQ Composite ended at 4,686.50, down 1.01%, the Dow Jones Industrial Average advanced 0.70%, to finish the day at 16,314.67, and the S&P 500 closed at 1,931.34, down 0.05%. The losses were broad based as six out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
Amgen Inc.'s stock lost 3.47%, to close the day at $138.53. The stock recorded a trading volume of 5.24 million shares, above its three months average volume of 3.72 million shares. Over the last one month and over the past three months, Amgen Inc.'s shares have declined 10.03% and 11.93%, respectively. Furthermore, the stock has lost 11.73% since the start of this year. The company's shares are trading 12.37% below their 200-day moving average. Additionally, Amgen Inc. traded at a PE ratio of 18.35 and has a Relative Strength Index (RSI) of 30.90. Sign up and read the free notes on AMGN at:
https://www.erionline.net/AMGN.pdf
On Friday, shares in ZIOPHARM Oncology Inc. recorded a trading volume of 5.70 million shares, higher than their three months average volume of 3.36 million shares. The stock ended the day 13.84% lower at $10.96. Although, ZIOPHARM Oncology Inc.'s stock has lost 11.04% in the previous three months, it has surged 30.48% in the last one month and 116.17% on YTD basis. The company is trading above its 200-day moving average by 9.98%. Furthermore, shares of ZIOPHARM Oncology Inc. have an RSI of 48.96. The complimentary notes on ZIOP can be downloaded in PDF format at:
https://www.erionline.net/ZIOP.pdf
Sarepta Therapeutics Inc.'s stock plummeted 6.71%, to close Friday's session at $36.27. The stock recorded a trading volume of 1.58 million shares, above its three months average volume of 1.30 million shares. Over the last one month and the previous three months, Sarepta Therapeutics Inc.'s shares have gained 6.15% and 16.03%, respectively. Additionally, the stock has rallied 150.66% since the start of this year. The company is trading 4.40% and 66.27% above its 50-day and 200-day moving averages, respectively. Furthermore, Sarepta Therapeutics Inc.'s stock has an RSI of 50.11. Register for free on Equity Research Institute and access the latest research on SRPT at:
https://www.erionline.net/SRPT.pdf
CTI BioPharma Corp.'s stock finished Friday's session 4.32% lower at $1.55. A total of 1.90 million shares were traded, which was above its three months average volume of 1.29 million shares. Over the previous three months and since the beginning of 2015, CTI BioPharma Corp.'s shares have declined 25.12% and 34.32%, respectively. However, the stock has gained 2.65% in the last one month. The company's shares are trading below their 50-day and 200-day moving averages by 9.18% and 22.78%, respectively. CTI BioPharma Corp.'s stock has an RSI of 45.61. The complete research on CTIC is available for free at:
https://www.erionline.net/CTIC.pdf
On Friday, shares in Agenus Inc. ended the session 13.10% lower at $5.04. The stock reported a trading volume of 2.93 million shares, above its three months average volume of 1.21 million shares. Agenus Inc.'s shares have plummeted 27.06% in the last one month and 37.70% in the previous three months. However, the stock has surged 26.95% on YTD basis. The company is trading 21.76% below its 200-day moving average. Moreover, shares of Agenus Inc. have an RSI of 26.12. Free in-depth research on AGEN is available at:
https://www.erionline.net/AGEN.pdf
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ERI has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.erionline.net.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE www.erionline.net
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article